PhenoLow concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1503-1510

  Yi, Gao ^a   He, Zhimin ^a   Zhou, Xinke ^a   Xian, Lewu ^a   Yuan, Taize ^a   Jia, Xiaoting ^a   Hong, Jian ^a   He, Lu ^a   Liu, Jifang ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

AMP activated protein kinase; Cellular senescence; Hepatocellular carcinoma; Metformin

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; BETA GALACTOSIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LYSINE; METFORMIN; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SERINE; SIRTUIN 1; SMALL INTERFERING RNA; AMP ACTIVATED PROTEIN KINASE KINASE; AMP-ACTIVATED PROTEIN KINASE KINASE; ANTIDIABETIC AGENT; PROTEIN KINASE; TP53 PROTEIN, HUMAN;

ACETYLATION; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME INHIBITION; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; CELL AGING; CELL CYCLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL AGING; CELL CYCLE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; METFORMIN; PROTEIN KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885084347     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2077     Document Type: Article

References (35)

1. Collado M, Blasco MA and Serrano M: Cellular senescence in cancer and aging. Cell 130: 223-233, 2007.
2. Collado M and Serrano M: Senescence in tumors: evidence from mice and humans. Nat Rev Cancer 10: 51-57, 2010.
3. Kang TW, Yevsa T, Woller N, et al: Senescence surveillance of pre-malignant hepatocytes limits live cancer development. Nature 479: 547-551, 2011.
4. Kuilman T, Michaloglou C, Mooi WJ and Peeper DS: The essence of senescence. Genes Dev 24: 2463-2479, 2010.
5. Dimri GP, Lee X, Basile G, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367, 1995.
6. Debacq-Chainiaux F, Erusalimsky JD, Campisi J and Toussaint O: Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4: 1798-1806, 2009.
7. Xue W, Zender L, Miething C, et al: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660, 2007.
8. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
9. Pollak M and Gonzalez-Angulo AM: Metformin and hepatic carcinogenesis. Cancer Prev Res 5: 500-502, 2012.
10. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y: In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 42: 922-933, 2012.
11. Chen HP, Shieh JJ, Chang CC, et al: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62: 606-615, 2013.
12. Liu J, Hou M, Yuan T, et al: Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair. Oncol Rep 28: 1406-1412, 2012.
13. Zhou G, Myers R, Li Y, Chen Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001.
14. Ben Sahra I, Regazzetti C, Robert G, et al: Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71: 4366-4372, 2011.
15. Del Barco S, Vazquez-Martin A, Cufí S, et al: Metformin: multi-faceted protection against cancer. Oncotarget 2: 896-917, 2011.
16. Wang W, Yang X, López de Silanes I, Carling D and Gorospe M: Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. J Biol Chem 278: 27016-2723, 2003.
17. Cairney CJ, Bilsland AE, Evans T, et al: Cancer cell senescence: a new frontier in drug development. Drug Discov Today 17: 269-276, 2012.
18. Qian Y, Zhang J, Yan B and Chen X: DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem 283: 2896-2905, 2007.
19. Mallette FA, Goumard S, Gaumont-Leclerc MF, Moiseeva O and Ferbeyre G: Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 23: 91-99, 2004.
20. Guarente L: Sir2 links chromatin silencing, metabolism and aging. Genes Dev 14: 1021-1026, 2000.
21. Nardella C, Clohessy JG, Alimonti A and Pandolfi PP: Pro-senescence therapy for cancer treatment. Nat Rev Cancer 11: 503-511, 2011.
22. Acosta JC and Gil J: Senescence: a new weapon for cancer therapy. Trends Cell Biol 22: 211-219, 2012.
23. Ewald JA, Desotelle JA, Wilding G and Jarrard DF: Therapy-induced senescence in cancer. J Natl Cancer Inst 102: 1536-1546, 2010.
24. Aljada A and Mousa SA: Metformin and neoplasia: implications and indications. Pharmacol Ther 133: 108-115, 2012.
25. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidence in taiwanese a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20, 2011.
26. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q and Kip KE: Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 97: 2347-2353, 2012.
27. Zwerschke W, Mazurek S, Stöckl P, Hütter E, Eigenbrodt E and Jansen-Dürr P: Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence. Biochem J 376: 403-411, 2003.
28. Mariño G, Ugalde AP, Salvador-Montoliu N, et al: Premature aging in mice activates a systemic metabolic response involving autophagy induction. Hum Mol Genet 17: 2196-2211, 2008.
29. Sung JY, Woo CH, Kang YJ, Lee KY and Choi HC: AMPK induces vascular smooth muscle cell senescence via LKB1 dependent pathway. Biochem Biophys Res Commun 413: 143-148, 2011.
30. Imamura K, Ogura T, Kishimoto A, Kaminishi M and Esumi H: Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 287: 562-567, 2001.
31. Jones RG, Plas DR, Kubek S, et al: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293, 2005.
32. Luo J, Nikolaev AY, Imai S, et al: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148, 2001.
33. Langley E, Pearson M, Faretta M, et al: Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21: 2383-2396, 2002.
34. Wang Y, Liang Y and Vanhoutte PM: SIRT1 and AMPK in regulating mammalian senescence: a critical review and a working model. FEBS Lett 585: 986-994, 2011.
35. Zu Y, Liu L, Lee MY, et al: SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res 106: 1384-1393, 2010.